Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 70 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pembrolizumab and chemoradiation for treating muscle-invasive, non-metastatic bladder cancer	Chemoradiotherapy , Pembrolizumab (Keytruda; MK-3475)	Bladder cancer	Urological Cancer	2023	View \| Download
Pembrolizumab and chemotherapy for resectable nonsmall-cell lung cancer	Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Pembrolizumab and chemotherapy with or without radiotherapy as an adjuvant therapy for treating newly diagnosed high-risk endometrial cancer	Chemotherapy , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2022	View \| Download
Pembrolizumab as adjuvant therapy for resected high-risk stage II melanoma	Pembrolizumab (Keytruda; MK-3475)	Melanoma	Skin Cancer	2020	View \| Download
Pembrolizumab for Advanced Hepatocellular Carcinoma – second line onwards	Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2018	View \| Download
Pembrolizumab for Hepatocellular Carcinoma – Adjuvant	Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Pembrolizumab for recurrent or metastatic nasopharyngeal cancer	Pembrolizumab (Keytruda; MK-3475)	Nasopharyngeal cancer	Head and Neck Cancer	2021	View \| Download
Pembrolizumab for renal cell carcinoma - adjuvant therapy post nephrectomy	Pembrolizumab (Keytruda; MK-3475)	Renal cell carcinoma (RCC)	Renal Cancer	2020	View \| Download
Pembrolizumab for Stage IV Colorectal Carcinoma – first line	Pembrolizumab (Keytruda; MK-3475)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2018	View \| Download
Pembrolizumab for treatment of solid tumours – second line	Pembrolizumab (Keytruda; MK-3475)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2021	View \| Download